Seaport Res Ptn Reaffirms Buy Rating for Hims & Hers Health (NYSE:HIMS)

Hims & Hers Health (NYSE:HIMS)‘s stock had its “buy” rating restated by analysts at Seaport Res Ptn in a research note issued on Friday, Zacks.com reports.

A number of other equities analysts have also weighed in on HIMS. Truist Financial upped their target price on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research note on Tuesday, February 27th. Guggenheim upped their price objective on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. TheStreet raised Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Piper Sandler upped their price target on Hims & Hers Health from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 27th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Moderate Buy” and an average price target of $14.85.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $12.55 on Friday. The company has a market capitalization of $2.69 billion, a P/E ratio of -114.05 and a beta of 0.91. The business has a 50-day moving average of $13.80 and a two-hundred day moving average of $10.14. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. During the same period last year, the company posted ($0.05) EPS. The business’s quarterly revenue was up 47.4% on a year-over-year basis. On average, equities analysts anticipate that Hims & Hers Health will post 0.1 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $13.95, for a total value of $34,916.85. Following the completion of the sale, the insider now directly owns 164,363 shares in the company, valued at approximately $2,292,863.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $13.95, for a total value of $34,916.85. Following the completion of the sale, the insider now owns 164,363 shares of the company’s stock, valued at approximately $2,292,863.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 97,208 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $9.58, for a total transaction of $931,252.64. Following the transaction, the chief executive officer now directly owns 51,653 shares in the company, valued at $494,835.74. The disclosure for this sale can be found here. Insiders have sold a total of 533,050 shares of company stock valued at $7,191,666 in the last three months. 31.63% of the stock is currently owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently modified their holdings of the stock. FNY Investment Advisers LLC bought a new position in Hims & Hers Health in the fourth quarter valued at approximately $48,000. Belpointe Asset Management LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth about $76,000. EMC Capital Management boosted its holdings in Hims & Hers Health by 80.0% in the third quarter. EMC Capital Management now owns 12,000 shares of the company’s stock valued at $79,000 after acquiring an additional 5,332 shares during the last quarter. Certuity LLC bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at $109,000. Finally, Corton Capital Inc. acquired a new stake in shares of Hims & Hers Health during the third quarter worth $122,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.